VioQuest Pharmaceuticals Completes Enrollment of Phase I Trial of Lenocta(TM)
enroll patients." About Lenocta(TM) Lenocta(TM) is an inhibitor of multiple protein tyrosine phosphatases
(PTPases), specifically the SRC homology ptpase
(SHP-1 & SHP-2) and PTB-1B,
based on data from several preclinical studies conducted at the Cleveland
Clinic. These intracellular enzymes are involved...